New combo tackles Hard-to-Treat myeloma
NCT ID NCT01562405
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug, sotatercept, combined with two standard treatments (lenalidomide or pomalidomide plus dexamethasone) in 33 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is to find the safest dose of sotatercept and begin to see if the combination can shrink tumors and improve anemia and bone damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.